logo-loader
viewArix Bioscience PLC

Arix Bioscience Plc portfolio company Iterum Therapeutics updates on its antibiotic drug

Arix Bioscience Plc (LON:ARIX) portoflio company Iterum Therapeutics Plc (NASDAQ:ITRM) CEO Corey Fishman tells Proactive's Christine Corrado the Dublin, Ireland based clinical stage biopharma company is in Phase 3 with its antibiotic drug Sulopenem.

Fishman says the company is developing the drug to treat multi-drug resistant infections, and stands out from its peers because Sulopenem is both an oral and IV drug, and he says there has not been a new oral product in this area in two decades.

Fishman says trials are expected to finish in the second half 2019.

Quick facts: Arix Bioscience PLC

Price: 119 GBX

LSE:ARIX
Market: LSE
Market Cap: £161.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read